Geron Co. (NASDAQ:GERN) Receives $7.25 Average Price Target from Analysts

Geron Co. (NASDAQ:GERN) has received a consensus recommendation of “Buy” from the twelve research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $6.91.

Several equities analysts recently commented on GERN shares. Barclays upgraded shares of Geron to a “strong-buy” rating in a research note on Friday, November 29th. HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Geron in a research report on Tuesday, December 10th. B. Riley lowered their target price on shares of Geron from $5.50 to $3.50 and set a “buy” rating on the stock in a report on Tuesday. Finally, Needham & Company LLC boosted their price target on Geron from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, January 13th.

Geron Stock Performance

Shares of NASDAQ GERN opened at $2.58 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The firm has a market cap of $1.56 billion, a price-to-earnings ratio of -8.05 and a beta of 0.53. The stock’s fifty day moving average price is $3.11 and its two-hundred day moving average price is $3.87. Geron has a one year low of $1.64 and a one year high of $5.34.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. RTW Investments LP acquired a new stake in shares of Geron in the 3rd quarter valued at $200,268,000. Vanguard Group Inc. lifted its position in shares of Geron by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 33,538,822 shares of the biopharmaceutical company’s stock worth $118,727,000 after buying an additional 1,088,912 shares during the last quarter. State Street Corp boosted its stake in Geron by 28.4% in the third quarter. State Street Corp now owns 28,961,671 shares of the biopharmaceutical company’s stock valued at $131,486,000 after buying an additional 6,413,204 shares in the last quarter. Janus Henderson Group PLC grew its position in Geron by 20.0% in the fourth quarter. Janus Henderson Group PLC now owns 27,082,461 shares of the biopharmaceutical company’s stock valued at $95,769,000 after acquiring an additional 4,516,615 shares during the last quarter. Finally, Holocene Advisors LP acquired a new position in Geron during the third quarter worth about $82,498,000. 73.71% of the stock is currently owned by institutional investors and hedge funds.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.